The NEO-CYT study, sponsored by Fondazione Melanoma Onlus, will be evaluating MDNA11 in front-line therapy for resectable ...
17m
Medicenna Therapeutics Corp.: Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook
ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, ...
Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback